Agendia Pivotal role to play in iSpy-2 of First Instance for the 12 drugs breast cancer trial, 20 leading cancer centers U.S. involved HUNTINGTON BEACH, California and Amsterdam, March 17, 2010 / PRNewswire / - Agendia, a world leader in molecular diagnostics for cancer, announced participate today that the highly anticipated I-Spy 2 in breast cancer, will be launched during the first of nearly two research sites. I-Spy 2 is an exciting and innovative new ... Low forms of Cyclin E reduces drug's effectiveness
